Celsion Corp. (CLSN)

1.69
NASDAQ : Health Technology
Prev Close 1.68
Day Low/High 1.67 / 1.76
52 Wk Low/High 1.35 / 2.88
Avg Volume 84.10K
Exchange NASDAQ
Shares Outstanding 21.39M
Market Cap 35.93M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Celsion Announces Publication Of Results Of National Institutes Of Health (NIH) Analysis Of ThermoDox® In Journal Of Vascular And Interventional Radiology

Celsion Announces Publication Of Results Of National Institutes Of Health (NIH) Analysis Of ThermoDox® In Journal Of Vascular And Interventional Radiology

NIH's Independent Analysis of Celsion's Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox ® Improves Overall Survival with Significance in Patients with Primary Liver Cancer NIH Analysis Supports the OPTIMA...

Celsion's GEN-1 Immunotherapy Highlighted In Oppenheimer's Expert Call On Ovarian Cancer Treatment Landscape And Emerging Opportunities

Celsion's GEN-1 Immunotherapy Highlighted In Oppenheimer's Expert Call On Ovarian Cancer Treatment Landscape And Emerging Opportunities

Presentation Slides Available on Celsion's Website LAWRENCEVILLE, N.J, Aug.

Celsion Announces Data Lock For First Interim Analysis In OPTIMA Phase III Study Of ThermoDox® In Primary Liver Cancer

Celsion Announces Data Lock For First Interim Analysis In OPTIMA Phase III Study Of ThermoDox® In Primary Liver Cancer

Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Celsion Corporation For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Celsion Corporation For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

NEW YORK, April 11, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Celsion...

Celsion Corporation To Present At Upcoming Investor Conferences

Celsion Corporation To Present At Upcoming Investor Conferences

Company to Discuss its Ongoing Pivotal Phase III and its Phase II Clinical Studies in Oncology

Celsion Announces Ovarian Cancer Expert Presentation At Oppenheimer & Co. Investor Event

Celsion Announces Ovarian Cancer Expert Presentation At Oppenheimer & Co. Investor Event

Discussion Included Overview of Ovarian Cancer Treatment Landscape and Celsion's Immunotherapy Product Candidate, GEN-1 Presentation Available on Celsion's Website

Celsion Announces ThermoDox® HEAT Study Presentation At Korean Liver Cancer Association's 12th Annual Scientific Meeting

Celsion Announces ThermoDox® HEAT Study Presentation At Korean Liver Cancer Association's 12th Annual Scientific Meeting

-Thesis Supporting the Phase III OPTIMA Study Chosen for the Presidential Selection Lecture by the Academic Committee - - Celsion to Host Symposium on Hepatocellular Carcinoma at International Liver Congress 2018 in April -

Celsion Provides Summary Of Research And Development Day Held On October 12, 2017

Celsion Provides Summary Of Research And Development Day Held On October 12, 2017

Leading Ovarian Cancer and Immunotherapy Experts Discuss GEN-1 Clinical Programs in Newly Diagnosed Stage III/IV Ovarian Cancer Patients

Celsion Provides Summary Of Research And Development Day Held On Thursday, October 12, 2017

Celsion Provides Summary Of Research And Development Day Held On Thursday, October 12, 2017

Leading Liver Cancer Experts Discuss ThermoDox® Clinical Programs in Primary Liver Cancer

Celsion To Host Research And Development (R&D) Day On Thursday, October 12, 2017

Celsion To Host Research And Development (R&D) Day On Thursday, October 12, 2017

Leading Experts to Discuss Clinical Programs in Primary Liver Cancer and Ovarian Cancer

Celsion To Host Research And Development Update October 12, 2017

Celsion To Host Research And Development Update October 12, 2017

Leading Experts to Discuss Clinical Programs in Primary Liver Cancer and Ovarian Cancer

Celsion Announces Presentation Of OVATION Study Findings At The Upcoming AACR Special Conference

Celsion Announces Presentation Of OVATION Study Findings At The Upcoming AACR Special Conference

Company to Report Final Clinical and Translational Research Data

Celsion Corporation Reports Second Quarter 2017 Financial Results And Provides Business Update

Celsion Corporation Reports Second Quarter 2017 Financial Results And Provides Business Update

Company to Hold Conference Call on Tuesday, August 15, 2017 at 11:00 a.m. ET

TheStreet Quant Rating: D- (Sell)